pS2 (TFF1) is a 6.5 kDa secreted protein belonging to the trefoil factor family, characterized by a disulfide-rich "trefoil domain" critical for epithelial protection and repair . It is estrogen-regulated in breast tissue and plays roles in mucosal healing, tumor progression, and response to endocrine therapies . pS2 expression is observed in 60% of breast carcinomas, particularly in estrogen receptor-positive tumors .
The following antibodies are widely used in research, with distinct epitope specificities and applications:
Anti-pSer2 antibodies exhibit distinct affinities depending on the location of phosphorylated serine residues (pSer2) within the 52-repeat C-terminal domain (CTD) of RNA polymerase II:
E1Z3G: Highest affinity for pSer2 in central heptads (e.g., heptad 4, K<sub>d</sub> = 0.5 nM) vs. N-terminal heptad 1 (K<sub>d</sub> = 3.2 nM) .
EPR18855/2G1: Preferential binding to C-terminal heptads (e.g., peptide 37 showed 25–40× enhanced binding) .
Phosphorylation at adjacent residues modulates pSer2 recognition:
pSer7 (−2 position): Enhances E1Z3G and 2G1 binding by 4–6× .
pThr4/pSer5 (+2/+3 positions): Blocks recognition by EPR18855 and 2G1 .
pS2 antibodies are validated for diverse techniques:
Epitope Accessibility:
Cross-Reactivity:
Validation:
FPS2 Antibody catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.
Validation requires a combination of controls:
Positive controls: Use tissues/cell lines with confirmed FPS2 expression (e.g., estrogen receptor-positive breast cancer samples) .
Negative controls:
| Control Type | Purpose | Priority | Source |
|---|---|---|---|
| Knockout tissue | Confirm absence of signal | High | |
| Peptide blocking | Verify target specificity | Medium | |
| Secondary-only | Detect background noise | High |
Fixation: Avoid over-fixation with paraformaldehyde (>4% may mask epitopes).
Permeabilization: Use 0.1% Triton X-100 for intracellular staining.
Titration: Test antibody dilutions (1:50–1:500) using a cell line with known FPS2 expression (e.g., MCF-7) . Validate with fluorescence-minus-one (FMO) controls.
Post-translational modifications: FPS2 is glycosylated; use deglycosylation enzymes (e.g., PNGase F) in WB to confirm band identity .
Epitope accessibility: Paraffin embedding in IHC may obscure epitopes; antigen retrieval (pH 9.0 buffer) improves detection .
Quantitative comparison: Normalize IHC signal intensity to housekeeping proteins (e.g., β-actin) via multiplex fluorescence .
Protein array screening: Test against >19,000 human proteins (HuProt™ array). Prioritize Z-scores >30 and S-scores >2.5 for specificity .
CRISPR validation: Knock out FPS2 in HEK-293 cells and compare signal loss to wild-type .
| Metric | Threshold | Interpretation |
|---|---|---|
| Z-score | >30 | Strong binding affinity |
| S-score | >2.5 | High target specificity |
Orthogonal validation: Correlate IHC results with RNA-seq data for TFF1 (FPS2 gene) using platforms like TCGA.
Machine learning: Apply LASSO regression to identify confounding variables (e.g., sample fixation time) that affect antibody performance .
Pre-clearing: Incubate lysate with protein A/G beads before antibody exposure.
Alternative buffers: Replace TBST with high-stringency PBS-T + 0.5% casein.
Fragment analysis: Use reducing vs. non-reducing conditions to distinguish monomeric (7 kDa) vs. dimeric FPS2 .
ROC analysis: Calculate sensitivity/specificity using clinical cohorts (e.g., breast cancer vs. normal tissue).
Meta-analysis: Aggregate data from public repositories (e.g., CPTAC) to assess consistency across platforms .